Telisotuzumab (ABT-700) (i.p., 2.5-40 mg/kg, twice a week, 90 days) effectively antagonizes constitutively activated c-Met and downstream signaling, thereby inhibiting tumor growth in SCID mice with Hs746T cells[1].
| Animal Model: | SCID mice with Hs746T cells[1] |
| Dosage: | 2.5-40 mg/kg |
| Administration: | i.p., twice a week, 90 days |
| Result: | Reduced total and phosphorylated c-Met as well as phosphorylated Akt and Erk.
Complete tumor regression at doses above 10 mg/kg but no effective inhibition of tumor growth at doses below 5mg/kg.
|
